TP53 and Miyoshi myopathy: Our data demonstrate that there is a significant difference between commercial and primary cell lines at the molecular level, including the transcriptome, expression of mesothelial markers and proteins associated with MM pathogenesis including p53, metabolic profile, status of the tumor suppressor genes CDKN2A and NF2 and their products.